Status:
COMPLETED
Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients
Lead Sponsor:
Pfizer
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
This study is to evaluate available local data in Iraqi patients with moderate to severe psoriasis on Enbrel treatment with regards to efficacy, treatment regimen adherence and patient characterizatio...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of moderate to severe plaque psoriasis receiving etanercept treatment for a minimum duration of 1 year.
- Age ≥18 years old.
- No history of using a biological treatment, other than etanercept, for treatment of moderate to severe plaque psoriasis or any other reason.
Exclusion
- Etanercept use for treatment moderate to severe plaque psoriasis less than 1 year duration.
- Previous use of other biological treatments for any reason
Key Trial Info
Start Date :
July 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2020
Estimated Enrollment :
486 Patients enrolled
Trial Details
Trial ID
NCT04398732
Start Date
July 5 2020
End Date
October 1 2020
Last Update
November 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
Baghdad, Iraq